Self-amplifying RNA (saRNA) vaccines built on a replication-deficient alphavirus backbone such as VEEV, offer several advantages for vaccine development. Sequences for relatively large antigens can be encoded and efficiently expressed, at low vaccine doses. Practical and efficient delivery of the ...
RNA vaccine candidates for the global SARS-CoV-2 pandemic. Both conventional and self-amplifying RNAs have shown protective immunization in preclinical studies against multiple infectious diseases including influenza, RSV, Rabies, Ebola, and HIV-1. Self-amplifying RNAs have shown enhanced antigen ...
Self-amplifying mRNA (samRNA) is rapidly emerging as a well-tolerated, scalable and widely-applicable platform technology which can be used to develop multiple vaccines simply by changing the sequence of the antigen (the target ...
Revolutionizing Vaccine Development Rapid response to emerging diseases is critical when developing a vaccine. Long RNA (mRNA and saRNA) is at the forefront of vaccine development. Benefits of saRNA saRNA vaccines can be developed in a fraction of the time it takes to develop a conventional vaccine...
self-amplifying alphavirus Introduction RNA is a potent platform for gene delivery, both vaccine antigens and therapeutic proteins, although there are necessarily differences in the interaction of the immune system with the expressed proteins. Self-amplifying RNA (saRNA) offers a considerable advantage ...
Figure 6. A Single Dose of Self-Amplifying RNA Vaccine Gives Equivalent Protection to Electroporated DNA and Greater Protection than mRNA Encoding the Same Gene (A) BALB/c mice were primed i.m. with 1.5 μg Cal’09 H1N1 as DNA or self-amplifying RNA. RNA was delivered as a formulation...
“strong immune response and the potential for extended duration of protection.”The vaccine is intended for primary immunization (2 doses) as well as booster immunization in adults. Kostaive is the “world’s first approved product applying self-amplifying mRNA technolo...
Arcturus Therapeutics Holdings Inc. today shared topline data from an ongoing Phase 1/2/3 trial evaluating ARCT-154, Arcturus’ self-amplifying mRNA vaccine candidate against COVID-19 disease caused by the SARS-CoV-2 virus.
[2] Spurred on by Moderna and Pfizer's success, a Belgian biotech has big ambitions for its self-amplifying RNA vaccine play. Retrieved September 8, 2021, from https://endpts.com/spurred-on-by-moderna-and-pfizers-success-a-belgian-biotech-has-big-ambitions-for-its-self-amplifying-rna-vacc...
(Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi) announced today that it has received approval for a partial amendment to the manufacturing and marketing approval of “KOSTAIVE® for Intramuscular Injection,” a self-amplifying mRNA vaccine for...